NewsAwards
Awards
Patent Drafted by Liu Shen Wins Gold Award at the 26th China Patent Awards
2026-09-01

On August 28, 2026, the China National Intellectual Property Administration (CNIPA) officially announced the winners of the 26th China Patent Awards. An invention patent entitled “Polypeptides, Methods for Their Production and Uses” (Patent No. ZL201811438582.6), owned by Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. (Jinbo Bio-Pharmaceutical) and drafted and prosecuted by Liu Shen & Associates, was awarded the prestigious China Patent Gold Award following a selection process jointly organized by CNIPA and the World Intellectual Property Organization (WIPO), distinguishing itself among millions of patents in force in China.

专利金奖.png

专利金奖1.png

The patented technology encompasses the atomic-level structural analysis of the core functional regions of recombinant type III humanized collagen and methods for its industrial-scale production. It addresses key technical challenges associated with conventional collagen products, including immunogenicity and the toxicity of cross-linking agents, and enables the large-scale production of recombinant humanized collagen macromolecules with a stable triple-helical structure. Products developed using this patented technology have been administered in more than four million units across applications including medical aesthetics, gynecological tissue repair, and cardiovascular medicine, with no immunogenic adverse events reported in clinical use. These achievements demonstrate the technology's significant technical advancements and substantial potential for industrial commercialization. 

Jointly organized by CNIPA and WIPO, the China Patent Awards represent the highest distinction in China's patent sector. The evaluation process considers four key criteria: patent quality, technological advancement, the implementation and effectiveness of patent exploitation and protection measures, and social benefits and future development prospects. Only 30 invention patents received Gold Awards in this year's selection. This recognition not only underscores Jinbo Bio-Pharmaceutical's original innovation capabilities but also highlights Liu Shen & Associates' expertise in developing and drafting high-value patents in the biopharmaceutical sector. The firm remains committed to its rigorous and pragmatic approach to client service, helping innovators build robust, high-quality patent portfolios and strengthen their competitive positions while facilitating the efficient commercialization of technological achievements.

Patent Prosecution Team: ZHANG Wenhui and LI Weixiang.